Nisa Investment Advisors LLC Has $10.71 Million Stake in Zimmer Biomet Holdings Inc (ZBH)

Nisa Investment Advisors LLC grew its stake in Zimmer Biomet Holdings Inc (NYSE:ZBH) by 15.5% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 81,463 shares of the medical equipment provider’s stock after purchasing an additional 10,904 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Zimmer Biomet were worth $10,710,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. First Hawaiian Bank acquired a new stake in Zimmer Biomet during the 3rd quarter worth $459,000. Bank of Montreal Can increased its holdings in Zimmer Biomet by 15.1% during the 3rd quarter. Bank of Montreal Can now owns 218,333 shares of the medical equipment provider’s stock worth $28,703,000 after purchasing an additional 28,591 shares in the last quarter. Bridge Creek Capital Management LLC increased its holdings in Zimmer Biomet by 2.3% during the 3rd quarter. Bridge Creek Capital Management LLC now owns 23,559 shares of the medical equipment provider’s stock worth $3,097,000 after purchasing an additional 525 shares in the last quarter. Town & Country Bank & Trust CO dba First Bankers Trust CO bought a new position in Zimmer Biomet during the 3rd quarter worth about $217,000. Finally, Murphy Capital Management Inc. bought a new position in Zimmer Biomet during the 3rd quarter worth about $245,000. 87.25% of the stock is currently owned by institutional investors.

In related news, CEO Bryan C. Hanson acquired 410 shares of the firm’s stock in a transaction dated Friday, August 31st. The stock was bought at an average price of $123.03 per share, for a total transaction of $50,442.30. Following the acquisition, the chief executive officer now directly owns 25,487 shares of the company’s stock, valued at $3,135,665.61. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Tony W. Collins sold 2,778 shares of the firm’s stock in a transaction dated Tuesday, July 31st. The shares were sold at an average price of $125.77, for a total transaction of $349,389.06. The disclosure for this sale can be found here. 0.71% of the stock is owned by company insiders.

A number of research firms have issued reports on ZBH. Argus cut Zimmer Biomet from a “buy” rating to a “hold” rating in a report on Friday, June 22nd. Zacks Investment Research cut Zimmer Biomet from a “hold” rating to a “sell” rating in a report on Wednesday. Piper Jaffray Companies increased their target price on Zimmer Biomet from $110.00 to $120.00 and gave the stock a “neutral” rating in a report on Monday, July 30th. ValuEngine upgraded Zimmer Biomet from a “sell” rating to a “hold” rating in a report on Wednesday, July 25th. Finally, Jefferies Financial Group increased their target price on Zimmer Biomet to $145.00 and gave the stock a “buy” rating in a report on Monday, July 30th. Three research analysts have rated the stock with a sell rating, nine have given a hold rating and fifteen have issued a buy rating to the company’s stock. Zimmer Biomet has an average rating of “Hold” and an average price target of $135.33.

Shares of NYSE ZBH opened at $124.40 on Friday. The stock has a market capitalization of $26.11 billion, a PE ratio of 15.78, a P/E/G ratio of 2.35 and a beta of 1.08. The company has a debt-to-equity ratio of 0.78, a current ratio of 2.41 and a quick ratio of 1.25. Zimmer Biomet Holdings Inc has a fifty-two week low of $104.28 and a fifty-two week high of $134.55.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Friday, July 27th. The medical equipment provider reported $1.92 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.88 by $0.04. The company had revenue of $2.01 billion during the quarter, compared to analysts’ expectations of $1.99 billion. Zimmer Biomet had a return on equity of 13.53% and a net margin of 21.67%. Zimmer Biomet’s revenue for the quarter was up 3.0% compared to the same quarter last year. During the same quarter last year, the company earned $2.08 EPS. As a group, sell-side analysts forecast that Zimmer Biomet Holdings Inc will post 7.66 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 31st. Stockholders of record on Friday, September 28th will be issued a $0.24 dividend. This represents a $0.96 annualized dividend and a dividend yield of 0.77%. The ex-dividend date is Thursday, September 27th. Zimmer Biomet’s payout ratio is 11.96%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.

Read More: How much money do you need to begin day trading?

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings Inc (NYSE:ZBH).

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply